Please login to the form below

Not currently logged in
Email:
Password:

Former Astellas regulatory lead joins Oxular

Robert Waters becomes regulatory affairs VP

Oxford, UK-based retinal therapeutics specialist Oxular has appointed Robert Waters as vice president of regulatory affairs.

Waters brings over 15 years of expertise in the development and registration of products in ophthalmology to the firm, most recently as global regulatory lead for urology and ophthalmology projects at Astellas.

Prior to this, Waters served as head of European regulatory affairs development and head of emerging markets, EMEA at Allergan, having previously been its head of ophthalmology and head of regulatory development.

Tom Cavanagh, chief executive of Oxular, said: “We are delighted to welcome Robert to the Oxular team.

“Robert's deep knowledge in global regulation combined with his extensive experience in progressing ophthalmology projects to approval will be a great asset to the Company as we look to bring new ophthalmic products to market.

“As a young company, we are proud to attract somebody of Robert's calibre within the ophthalmology field and we believe that he will play a key role in helping us to achieve our goal of building a global ophthalmic franchise based on the successful development and commercialisation of our innovative and much needed treatments for retinal diseases.”

19th December 2016

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics